Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The primary purpose of this study is to investigate the safety of Tasfygo.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• 1\. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Locations
Other Locations
Japan
#Eisai Trial Site 1
RECRUITING
Tokyo
Contact Information
Primary
Eisai Inquiry Service
eisai-chiken_hotline@hhc.eisai.co.jp
Time Frame
Start Date: 2025-07-10
Estimated Completion Date: 2032-11-20
Participants
Target number of participants: 60
Treatments
Tasfygo tablet 35 milligrams (mg)
Related Therapeutic Areas
Sponsors
Leads: Eisai Co., Ltd.